FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3025972894> ?p ?o ?g. }

• W3025972894 endingPage "m1844" @default.
• W3025972894 startingPage "m1844" @default.
• W3025972894 abstract "Abstract Objective To assess the effectiveness of hydroxychloroquine in patients admitted to hospital with coronavirus disease 2019 (covid-19) pneumonia who require oxygen. Design Comparative observational study using data collected from routine care. Setting Four French tertiary care centres providing care to patients with covid-19 pneumonia between 12 March and 31 March 2020. Participants 181 patients aged 18-80 years with documented severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia who required oxygen but not intensive care. Interventions Hydroxychloroquine at a dose of 600 mg/day within 48 hours of admission to hospital (treatment group) versus standard care without hydroxychloroquine (control group). Main outcome measures The primary outcome was survival without transfer to the intensive care unit at day 21. Secondary outcomes were overall survival, survival without acute respiratory distress syndrome, weaning from oxygen, and discharge from hospital to home or rehabilitation (all at day 21). Analyses were adjusted for confounding factors by inverse probability of treatment weighting. Results In the main analysis, 84 patients who received hydroxychloroquine within 48 hours of admission to hospital (treatment group) were compared with 89 patients who did not receive hydroxychloroquine (control group). Eight additional patients received hydroxychloroquine more than 48 hours after admission. In the weighted analyses, the survival rate without transfer to the intensive care unit at day 21 was 76% in the treatment group and 75% in the control group (weighted hazard ratio 0.9, 95% confidence interval 0.4 to 2.1). Overall survival at day 21 was 89% in the treatment group and 91% in the control group (1.2, 0.4 to 3.3). Survival without acute respiratory distress syndrome at day 21 was 69% in the treatment group compared with 74% in the control group (1.3, 0.7 to 2.6). At day 21, 82% of patients in the treatment group had been weaned from oxygen compared with 76% in the control group (weighted risk ratio 1.1, 95% confidence interval 0.9 to 1.3). Eight patients in the treatment group (10%) experienced electrocardiographic modifications that required discontinuation of treatment. Conclusions Hydroxychloroquine has received worldwide attention as a potential treatment for covid-19 because of positive results from small studies. However, the results of this study do not support its use in patients admitted to hospital with covid-19 who require oxygen." @default.
• W3025972894 created "2020-05-21" @default.
• W3025972894 creator A5001192345 @default.
• W3025972894 creator A5003385416 @default.
• W3025972894 creator A5007247451 @default.
• W3025972894 creator A5010754943 @default.
• W3025972894 creator A5014403667 @default.
• W3025972894 creator A5014455126 @default.
• W3025972894 creator A5016142382 @default.
• W3025972894 creator A5018300785 @default.
• W3025972894 creator A5018477126 @default.
• W3025972894 creator A5026118547 @default.
• W3025972894 creator A5030711598 @default.
• W3025972894 creator A5032754634 @default.
• W3025972894 creator A5034929943 @default.
• W3025972894 creator A5035314875 @default.
• W3025972894 creator A5038981809 @default.
• W3025972894 creator A5039798351 @default.
• W3025972894 creator A5048827235 @default.
• W3025972894 creator A5051956323 @default.
• W3025972894 creator A5053696894 @default.
• W3025972894 creator A5056136082 @default.
• W3025972894 creator A5062315921 @default.
• W3025972894 creator A5063663700 @default.
• W3025972894 creator A5067646560 @default.
• W3025972894 creator A5067854644 @default.
• W3025972894 creator A5069373819 @default.
• W3025972894 creator A5071996090 @default.
• W3025972894 creator A5074097531 @default.
• W3025972894 creator A5076759724 @default.
• W3025972894 creator A5078390860 @default.
• W3025972894 creator A5081368271 @default.
• W3025972894 creator A5082364166 @default.
• W3025972894 creator A5082960590 @default.
• W3025972894 creator A5084613181 @default.
• W3025972894 creator A5089306109 @default.
• W3025972894 date "2020-05-14" @default.
• W3025972894 modified "2023-10-18" @default.
• W3025972894 title "Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data" @default.
• W3025972894 cites W1803784511 @default.
• W3025972894 cites W2009187570 @default.
• W3025972894 cites W2038513239 @default.
• W3025972894 cites W2110818436 @default.
• W3025972894 cites W2118400571 @default.
• W3025972894 cites W2131512878 @default.
• W3025972894 cites W2168639902 @default.
• W3025972894 cites W2280404143 @default.
• W3025972894 cites W2298338128 @default.
• W3025972894 cites W2581766282 @default.
• W3025972894 cites W3001118548 @default.
• W3025972894 cites W3009577418 @default.
• W3025972894 cites W3009885589 @default.
• W3025972894 cites W3010930696 @default.
• W3025972894 cites W3012379316 @default.
• W3025972894 cites W3012771079 @default.
• W3025972894 cites W3013058647 @default.
• W3025972894 cites W3013174684 @default.
• W3025972894 cites W3013198879 @default.
• W3025972894 cites W3013450525 @default.
• W3025972894 cites W3013577603 @default.
• W3025972894 cites W3013653866 @default.
• W3025972894 cites W3013899502 @default.
• W3025972894 cites W3015848059 @default.
• W3025972894 cites W3015907249 @default.
• W3025972894 cites W3165656738 @default.
• W3025972894 doi "https://doi.org/10.1136/bmj.m1844" @default.
• W3025972894 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7221472" @default.
• W3025972894 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32409486" @default.
• W3025972894 hasPublicationYear "2020" @default.
• W3025972894 type Work @default.
• W3025972894 sameAs 3025972894 @default.
• W3025972894 citedByCount "324" @default.
• W3025972894 countsByYear W30259728942020 @default.
• W3025972894 countsByYear W30259728942021 @default.
• W3025972894 countsByYear W30259728942022 @default.
• W3025972894 countsByYear W30259728942023 @default.
• W3025972894 crossrefType "journal-article" @default.
• W3025972894 hasAuthorship W3025972894A5001192345 @default.
• W3025972894 hasAuthorship W3025972894A5003385416 @default.
• W3025972894 hasAuthorship W3025972894A5007247451 @default.
• W3025972894 hasAuthorship W3025972894A5010754943 @default.
• W3025972894 hasAuthorship W3025972894A5014403667 @default.
• W3025972894 hasAuthorship W3025972894A5014455126 @default.
• W3025972894 hasAuthorship W3025972894A5016142382 @default.
• W3025972894 hasAuthorship W3025972894A5018300785 @default.
• W3025972894 hasAuthorship W3025972894A5018477126 @default.
• W3025972894 hasAuthorship W3025972894A5026118547 @default.
• W3025972894 hasAuthorship W3025972894A5030711598 @default.
• W3025972894 hasAuthorship W3025972894A5032754634 @default.
• W3025972894 hasAuthorship W3025972894A5034929943 @default.
• W3025972894 hasAuthorship W3025972894A5035314875 @default.
• W3025972894 hasAuthorship W3025972894A5038981809 @default.
• W3025972894 hasAuthorship W3025972894A5039798351 @default.
• W3025972894 hasAuthorship W3025972894A5048827235 @default.
• W3025972894 hasAuthorship W3025972894A5051956323 @default.
• W3025972894 hasAuthorship W3025972894A5053696894 @default.
• W3025972894 hasAuthorship W3025972894A5056136082 @default.
• W3025972894 hasAuthorship W3025972894A5062315921 @default.

• next